These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 23945203)
1. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature. Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203 [TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted MRI and 18F-FDG-PET/CT imaging: competition or synergy as diagnostic methods to manage sarcoma of the uterus? A systematic review of the literature. Dubreuil J; Tordo J; Rubello D; Giammarile F; Skanjeti A Nucl Med Commun; 2017 Jan; 38(1):84-90. PubMed ID: 27898647 [TBL] [Abstract][Full Text] [Related]
3. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700 [TBL] [Abstract][Full Text] [Related]
4. Role of Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849 [TBL] [Abstract][Full Text] [Related]
5. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas. Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788 [TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195 [TBL] [Abstract][Full Text] [Related]
7. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging. Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of Kassem TW; Abdelaziz O; Emad-Eldin S Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778 [TBL] [Abstract][Full Text] [Related]
9. [Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma]. Rebollo Aguirre AC; Ramos Font C; Bellón Guardia ME; Cabello García D; Gallego Peinado M; Rodríguez Fernández A; Llamas Elvira JM Rev Esp Med Nucl; 2007; 26(4):189-95. PubMed ID: 17662185 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. Kakhki VR; Shahriari S; Treglia G; Hasanzadeh M; Zakavi SR; Yousefi Z; Kadkhodayan S; Sadeghi R Int J Gynecol Cancer; 2013 Nov; 23(9):1536-43. PubMed ID: 24172090 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Treglia G; Salsano M; Stefanelli A; Mattoli MV; Giordano A; Bonomo L Skeletal Radiol; 2012 Mar; 41(3):249-56. PubMed ID: 22072239 [TBL] [Abstract][Full Text] [Related]
12. The impact of Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508 [TBL] [Abstract][Full Text] [Related]
13. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis. Lin CY; Lin CL; Kao CH Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. Xiao Y; Wang L; Jiang X; She W; He L; Hu G Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912 [TBL] [Abstract][Full Text] [Related]
17. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. Wu LM; Hu JN; Hua J; Gu HY; Zhu J; Xu JR J Gastroenterol Hepatol; 2012 Mar; 27(3):472-80. PubMed ID: 21916986 [TBL] [Abstract][Full Text] [Related]
18. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review. Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies. Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131 [TBL] [Abstract][Full Text] [Related]
20. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]